Scoring systems to screen for diabetic peripheral neuropathy

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Yang, Zhirong ^a,b   Chen, Ru ^a   Zhang, Yuan ^c   Huang, Yuansheng ^a   Hong, Tianpei ^d   Sun, Feng ^a   Ji, Linong ^e   Zhan, Siyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c MCMASTER UNIVERSITY   (Canada)

^d PEKING UNIVERSITY THIRD HOSPITAL   (China)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

AGE; ARTICLE; BODY MASS; CLINICAL PROTOCOL; DIABETIC NEUROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; ELECTRODIAGNOSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PRIORITY JOURNAL; SCORING SYSTEM; SCREENING TEST; SYMPTOM; SYSTEMATIC REVIEW; VASCULAR DISEASE;

EID: 84961673109     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010974     Document Type: Article

References (80)

1. American Association of Electrodiagnostic Medicine. Guidelines in electrodiagnostic medicine. Muscle Nerve 1999;22(Suppl 8):S3-300.
2. Abbott, CA, Vileikyte, L, Williamson, S, Carrington, AL, Boulton, AJM. Multi-center study of the incidence and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998;21:1071-5.
3. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al.The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabetic Medicine 2002;19(5):377-84.
4. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG. Risk factors for diabetic peripheral sensory neuropathy: results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997;20(7):1162-7.
5. Albers JW, Brown MB, Sima AAF, Greene DA. Nerve conduction measures in mild diabetic neuropathy: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Neurology 1995;45(Suppl):A190-1.
6. American Diabetes Association, American Academy of Neurology. Consensus statement: Report and recommendation of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988;11(7):592-7.
7. American Diabeties Association. Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Muscle Nerve 1992;15(10):1143-70.
8. American Diabetes Association. Standardized measures in diabetic neuropathy. Diabetes Care 1996;19(1S):72S-92S.
9. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care 2013;36(Suppl 1):S11-67.
10. Bastyr EJ, Price KL, Bril V, MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clinical Therapeutics 2005;27(8):1278-94.
11. Bossuyt PM, Leeflang MM. Chapter 6: Developing criteria for including studies. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 [updated September 2008]. The Cochrane Collaboration, 2008.
12. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabetes Medicine 1998;15(6):508-14.
13. Boulton AJ. Treatment of symptomatic diabetic neuropathy 2003. Diabetes Metabolism Research and Reviews 2003;19(Suppl. 1):S16-21.
14. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004;27(6):1458-86.
15. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al.Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28(4):956-62.
16. Boulton AJM. Management of diabetic peripheral neuropathy. Clinical Diabetes 2005;23(1):9-15.
17. Boulton AJM. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes/Metabolism Research and Reviews 2008;24(Suppl 1):S3-6.
18. Bril V, Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002;25(11):2048-52.
19. Bril V, Tomioka S, Buchanan RA, Perkins BA, mTCNS Study Group. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabetes Medicine 2009;26(3):240-6.
20. Buchthal F. An Introduction to Electromyography. Copenhagen: Scandina-vian University Books, 1957.
21. Callaghan BC, Little AA, Feldman EL, Hughes RAC. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD007543.pub2].
22. Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 2002;25(3):476-81.
23. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53(8):1660-4.
24. Cornblath DR. Diabetic neuropathy: Diagnostic methods. Advanced Studies in Medicine 2004;4(8A):S650-61.
25. Creager MA, Luscher TF, Cosentino F, Beckman H. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108(12):1527-32.
26. Daube JR. Electrophysiologic testing in diabetic neuropathy. In: Dyck P, Thomas P editor(s). Diabetic Neuropathy. Philadelphia, PA: WB Saunders, 1999:222-38.
27. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29(7):1518-22.
28. Deeks JJ, Bossuyt PM, Gatsonis C (editors). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2009. Available from: http://srdta.cochrane.org. The Cochrane Collaboration.
29. Donofrio PD, Albers JW. AAEM minimonograph #34: polyneuropathy: classification by nerve conduction studies and electromyography. Muscle Nerve 1990;13(10):889-903.
30. Dros J, Wewerinke A, Bindels PJ, van Weert HC. Accuracy of monofilament testing to diagnose peripheral neuropathy: a systematic review. Annals of Family Medicine 2009;7(6):555-8.
31. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, et al. Human diabetic endoneural sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Annals of Neurology 1980;8(6):590-6.
32. Dyck PJ, Karnes J, O'Brien PC, Swanson CJ. Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology 1986;36(10):1300-8.
33. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988;11(1):21-32.
34. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995;45(6):1115-21.
35. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997;49(1):229-39.
36. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al.Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metabolism Research and Review 2011;27:620-8.
37. Dyck PJ, Carter RE, Litchy WJ. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy. Muscle Nerve 2011;44(3):340-5.
38. England JD, Gronseth GS, Franklin G, Miller RG, Asbury AK, Carter GT, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005;64(2):199-207.
39. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17(11):1281-9.
40. Feng Y, Schlösser FJ, Sumpio BE. The Semmes Weinstein monofilament examination as a screening tool for diabetic peripheral neuropathy. Journal of Vascular Surgery 2009;50(3):675-82.
41. Giannini C, Dyck PJ. Pathologic alterations in human diabetic polyneuropathy. In: Dyck PJ, Thomas PK editor(s). Diabetic Neuropathy. Philadelphia: WB Saunders, 1999:279-95.
42. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, et al.Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004;27(7):1591-7.
43. Kanji JN, Anglin RE, Hunt DL, Panju A. Does this patient with diabetes have large-fiber peripheral neuropathy?. JAMA 2010;303(15):1526-32.
44. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100.
45. Liu F, Bao Y, Hu R, Zhang X, Li H, Zhu D, et al.Screening and prevalence of peripheral neuropathy in type 2 diabetic outpatients: a randomized multicentre survey in 12 city hospitals of China. Diabetes Metabolism Research and Review 2010;26(6):481-9.
46. Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C editor(s). CochraneHandbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration, 2010. Available from: http://srdta.cochrane.org/.
47. Meijer JW, van Sonderen E, Blaauwwiekel EE, Smit AJ, Groothoff JW, Eisma WH, et al.Diabetic neuropathy examination: a hierarchical scoring system to diagnose distal polyneuropathy in diabetes. Diabetes Care 2000;23(6):750-3.
48. Meijer JW, Smit AJ, Sonderen EV, Groothoff JW, Eisma WH, Links TP. Symptom scoring systems to diagnose distal polyneuropathy in diabetes: the Diabetic Neuropathy Symptom score. Diabetic Medicine 2002;19(11):962-5.
49. Meijer JW, Bosma E, Lefrandt JD, Links TP, Smit AJ, Stewart RE, et al.Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores. Diabetes Care 2003;26(3):697-701.
50. Melton LJ III, Dyck PJ. Diabetic polyneuropathy. In: Dyck PJ, Thomas PK editor(s). Diabetic Neuropathy. 2. Philadelphia: W.B. Saunders, 1999:255-78.
51. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097.
52. Moreira RO, Castro AP, Papelbaum M, Appolinario JC, Ellinger VC, Coutinho WF, et al.Translation into Portuguese and assessment of the reliability of a scale for the diagnosis of diabetic distal polyneuropathy. Arquivos Brasileiros de Endocrinologia & Metabologia 2005;49(6):944-50.
53. Nasseri K, Strijers RLM, Dekhuijzen LS, Buster M, Bertelsmann FW. Reproducibility of different methods for diagnosing and monitoring diabetic neuropathy. Electromyography and Clinical Neurophysiology 1998;38:295-9.
54. Perkins BA, Bril V. Diabetic neuropathy: a review emphasizing diagnostic methods. Clinical Neurophysiology 2003;114(7):1167-75.
55. Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past present and future. Diabetes 1995;44(12):1355-61.
56. Ragnarson Tennvall G, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clinical Infectious Diseases 2004;39(Suppl 2):S132-9.
57. Rayman G. The National Diabetes Inpatient Audit Day. A great success and a powerful tool with which to improve inpatient diabetes care. Summary of the paper presented to Diabetes UK APC March 2010. http://diabetologists-abcd.org.uk/Shared_Documents/newsletters/ABCD_Newsletter_Spring2010.pdf.
58. Reiber GE, Vileikyte L, Boyko EJ, Del Aguila M, Smith DG, Lavery LA, et al.Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999;22:157-62.
59. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, BossuytPM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982-90.
60. Rutjes AWS, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PMM. Case-control and two-gate designs in diagnostic accuracy studies. Clinical Chemistry 2005;51(8):1335-41.
61. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Statistics in Medicine 2001;20(19):2865-84.
62. Singleton JR, Bixby B, Russell JW, Feldman EL, Peltier A, Goldstein J, et al. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. Journal of the Peripheral Nervous System 2008;13(3):218-27.
63. Smith AG, Singleton JR. Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. Journal of Diabetes Complications 2013;27(5):436-42.
64. Soliman E, Gellido C. Diabetic Neuropathy. eMedicine.com March 29, 2002.
65. Sugimoto K, Murakawa Y, Sima AA. Diabetic neuropathy - a continuing enigma. Diabetes Metabolism Research and Reviews 2000;16((6)):408-33.
66. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al.Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996;39(11):1377-84.
67. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al.Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285-93.
68. Thomas PK. Classification, differential diagnosis and staging of diabetic peripheral neuropathy. Diabetes 1997;46(Suppl 2):S54-7.
69. Valk GD, Nauta JJ, Strijers RL, Bertelsmann FW. Clinical examination versus neurophysiological examination in the diagnosis of diabetic polyneuropathy. Diabetic Medicine 1992;9(8):716-21.
70. Valk GD, de Sonnaville JJ, van Houtum WH, Heine RJ, van Eijk JT, Bouter LM, et al. The assessment of diabetic polyneuropathy in daily clinical practice: Reproducibility and validity of Semmes Weinstein monofilaments examination and clinical neurological examination. Muscle Nerve 1997;20(1):116-8.
71. Vijan S, Stevens DL, Herman WH, Funnell MM, Standiford CJ. Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Journal of General Internal Medicine 1997;12(9):567-80.
72. Vinik AI, Mehrabyan A. Diabetic neuropathies. The Medical Clinics of North America 2004;88(4):947-99.
73. Weintrob N, Amitay I, Lilos P, Shalitin S, Lazar L, Josefsberg Z. Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes. Journal of Diabetes and Its Complications 2007;21(1):13-9.
74. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36. [PUBMED: 22007046].
75. Wild S, Roglic G, Sicree R, Green A, King H. Globalburden of diabetes mellitus in the year 2000. The World Health Report 2001. World Health Organization 2001.
76. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53.
77. Won JC, Kwon HS, Kim CH, Lee JH, Park TS, Ko KS, et al. Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with Type 2 diabetes in Korea. Diabetic Medicine 2012;29(9):e290-6.
78. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nature Medicine 2006;12(1):62-6.
79. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36(2):150-4.
80. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, et al. The ALADIN Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoicacid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995;38:1425-33.